BMB401 F08 T4 form_1final

BMB401 F08 T4 form_1final - I, (Name) _ have neither...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
I, (Name) _________________________________________ have neither received nor given help BMB 401/506-Fall 2008 Fourth Examination Form 1 December 4, 2008 During the exam you should not be in possession of a beeper, cellular phone or any other electronics. Please place all electronic devices (turn them off!!!), books and papers in your book bag and place the bag against the wall of the room. Students who have electronic devices during the exam will be reported to the Honors Council. THESE ARE STANDARD SINGLE ANSWER MULTIPLE CHOICE QUESTIONS. THE POSSIBLE ANSWERS ARE LABELED A,B,C,D AND E. SELECT THE SINGLE BEST ANSWER AND MARK THE APPROPRIATE CIRCLE ON THE SCANTRON ANSWER SHEET. BUBBLE IN YOUR NAME AND ID# (C# ONLY PLEASE) . There are 38 questions. You will receive full credit for 36 correct answers. 1. One of the amino acids given below contributes a nitrogen atom to the biosynthesis of the purine ring and both nitrogen and carbon atoms to the biosynthesis of the pyrimidine ring. Which ONE? A. Glycine B. Aspartic acid C. Glutamine D. Glutamic acid E. Asparagine 2. Formation of one of the compounds given below constitutes the committed step in the de novo biosynthesis of purine nucleotides. Identify the intermediate. A. Ribose-5-phosphate B. 5-Phosphoribosyl-1-pyrophosphate C. Inosine monophosphate D. Phosphoribosylamine E. Glycinamide ribonucleotide 3. In the de novo pyrimidine biosynthesis ONE of the following compounds is the immediate precursor of a cytosine nucleotide. Which ONE? A. UTP B. UDP C. UMP D. Orotidine-5’-monophosphate E. None of the above 4. The cancer chemotherapeutic agent, methotrexate, acts as a folic acid antagonist by: A. Preventing the absorption of folic acid from the gut B. Preventing the transport of folic acid to the cancer cells C. Preventing the conversion of dihydrofolic acid to tetrahydrofolate D. Blocking the interconversion of single carbon folate intermediates E. Blocking the single carbon transfer to homocysteine 5. All of the following are true for the reduction of purine ribonucleotides to purine deoxyribonucleotides EXCEPT: A. It uses reducing equivalents whose ultimate source is NADPH B. It involves the same reductase system for both nucleotides C. It takes place at the level of ribonucleoside diphosphate D. It involves cleavage of the glycosidic bond in the sugar nucleotide 6. Lesch-Nyhan syndrome is characterized by a lack of: A. Adenosine deaminase B. Hypoxanthine guanine phosphoribosyltransferase (HGPRT) C. Guanylate kinase D. Adenine phosphoribosyltransferase E. De novo synthesis of purines 7. Assuming presence of preformed 5-phosphoribosyl-1- pyrophosphate, how many high-energy phosphate bonds (ATP equivalents) are required for the de novo biosynthesis of uridine triphosphate? Remember to include the ATP equivalents used in carbamoylphosphate synthesis. A.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This document was uploaded on 11/04/2011 for the course BMB 401 at University of Miami.

Page1 / 5

BMB401 F08 T4 form_1final - I, (Name) _ have neither...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online